Editor's note: This article is a stock pitch made by a member on CAPS, The Motley Fool's free investing community. The pitch is published UNEDITED and is the opinion of the CAPS member whose pitch it is, in this case: zzlangerhans.
Each week, Motley Fool editors cull a top stock idea from the pitches made on CAPS, the Motley Fool's 180,000-member free investing community. Want your idea considered for this series? Make a compelling pitch on CAPS with a minimum length of 400 words. Want to follow our weekly picks? Subscribe to our RSS feed or follow us on Twitter.
|Submitted On||Dec. 23, 2011|
|Stock Price at Underperform Recommendation||$1.74|
|Star Rating (out of 5)||*|
|Market Cap||$163 million|
Sources: S&P Capital IQ, Yahoo! Finance, and Motley Fool CAPS.
I've been itching to red thumb Zogenix since March, but a year filled with premature red thumbs made me too gun shy and the stock never rose up to meet my threshold. Now I find myself finally placing my red thumb at an entry price two thirds lower than when I started following the stock. I should have gone with my first instincts.
Zogenix suffers from the same problem as Somaxon, which Labopharm and many others suffered from before. They market a drug with limited commercial appeal whose revenues don't come close to the cost of producing and selling it. In the case of Zogenix it's superfluous triptan Sumavel, whose revenues seem to have topped out under 9M per quarter. Partner Astellas finally called it quits on Sumavel this month, which won't do much good for Zogenix's 20M+ quarterly burn rate.
The company has fortified their cash position recently at the expense of heavy dilution and debt, which can only control the hemorrhage temporarily. Their only long-term hope is Zohydro controlled-release hydrocodone for chronic pain, which should be submitted to the FDA in Q2 2012. You read that right. Their future rests on the regulatory and commercial success of a new prescription opiate. I'm sure investors in Pain Therapeutics and Acura are weeping quietly right now.
The Motley Fool is investors writing for investors. Dan Dzombak did not have a position in any of the companies mentioned in this article. Pitches must be compelling, made in the past 30 days, and be at least 400 words. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.